Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the
resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating
EGFR mutations.